Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases

被引：0

作者：

Ichinose, Kunihiro ^{[1
]}

Origuchi, Tomoki ^{[2
]}

Kawashiri, Shin-ya ^{[1
]}

Iwamoto, Naoki ^{[1
]}

Fujikawa, Keita ^{[1
]}

Aramaki, Toshiyuki ^{[1
]}

Kamachi, Makoto ^{[1
]}

Arima, Kazuhiko ^{[1
]}

Tamai, Mami ^{[1
]}

Nakamura, Hideki ^{[1
]}

Ida, Hiroaki ^{[1
]}

Kawakami, Atsushi ^{[1
]}

Eguchi, Katsumi ^{[1
]}

机构：

[1] Nagasaki Univ, Dept Rheumatol, Unit Translat Med, Grad Sch Biomed Sci, Nagasaki 8528501, Japan

[2] Nagasaki Univ, Dept Phys Therapy, Unit Rehabil, Grad Sch Biomed Sci, Nagasaki 8528501, Japan

来源：

RHEUMATOLOGY INTERNATIONAL | 2012年 / 32卷 / 02期

关键词：

Rheumatoid arthritis (RA); Adalimumab; Long-term; DAS28-CRP; ANTITUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; METHOTREXATE; RISK; TUBERCULOSIS; EFFICACY; THERAPY; DISEASE; SAFETY;

D O I：

10.1007/s00296-010-1770-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 +/- A 7.07 years old. The median duration of the disease was 7.43 +/- A 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 +/- A 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 +/- A 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up.

引用

页码：483 / 487

页数：5

共 50 条

[21] Long-term follow-up of a high-intensity exercise program in patients with rheumatoid arthritis
de Jong, Zuzana
Munneke, Marten
Kroon, Herman M.
van Schaardenburg, Dirkjan
Dijkmans, Ben A. C.
Hazes, Johanna M. W.
Vlieland, Theodora P. M. Vliet
CLINICAL RHEUMATOLOGY, 2009, 28 (06) : 663 - 671
[22] Physical Activity Coaching of Patients with Rheumatoid Arthritis in Everyday Practice: A Long-term Follow-up
Sjoquist, Emma S.
Brodin, Nina
Lampa, Jon
Jensen, Irene
Opava, Christina H.
MUSCULOSKELETAL CARE, 2011, 9 (02) : 75 - 85
[23] Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance
Harigai, Masayoshi
Tsuritani, Katsuki
Yoshizawa, Yuri
Atsumi, Tatsuya
Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2022, 32 (03) : 508 - 516
[24] LONG-TERM USE OF RITUXIMAB IN RHEUMATOID ARTHRITIS: 17 YEARS FOLLOW-UP
Ismajli, Mediola
Ionescu, Raluca
Moore, Samantha
Leandro, Maria
RHEUMATOLOGY, 2017, 56 : 142 - 142
[25] LONG-TERM FOLLOW-UP STUDY OF BIOLOGICAL THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS
Avila, M. G.
Alonso, A.
Lasanta, M. Lopez
Pluma, A.
Quesada, E.
Marsal, S.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 475 - 475
[26] Retinal Function in Patients with Adalimumab Treatment: Long-term Follow-up with Microperimetry
Szepessy, Zsuzsanna
Barboni, Mirella T. S.
Farkas, Alexandra
Nagy, Zoltan Zsolt
Nemeth, Janos
OCULAR IMMUNOLOGY AND INFLAMMATION, 2021, 29 (02) : 370 - 375
[27] A LONG-TERM FOLLOW-UP OF THORACOPLASTY CASES
EDWARDS, FR
LEGGAT, G
DAVIES, HM
THORAX, 1953, 8 (02) : 114 - 115
[28] Safety of adalimumab in long-term treatment of patients with rheumatoid arthritis
Schiff, M
Burmester, GR
Kent, J
Pangan, A
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P203 - P203
[29] 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study
Yamaguchi, Ayako
Hirata, Shintaro
Kubo, Satoshi
Fukuyo, Shunsuke
Hanami, Kentaro
Nakano, Kazuhisa
Nakayamada, Shingo
Saito, Kazuyoshi
Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2020, 30 (05) : 799 - 806
[30] The vegetative state: A report of two cases with a long-term follow-up
Avesani, R
Gambini, MG
Albertini, G
BRAIN INJURY, 2006, 20 (03) : 333 - 338

← 1 2 3 4 5 →